back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-04-18 14:56 Tx date 2024-04-17 |
$VERS
Verses AI Inc. |
Wilson, Kevin Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Special Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$26,582
+26,582 vol $1.00 each |
26,582 | |
| Filed 2024-04-18 14:55 Tx date 2021-09-27 |
$VERS
Verses AI Inc. |
Wilson, Kevin Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Special Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-03-28 07:55 Tx date 2024-03-27 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
56 - Grant of rights
|
+4,074 vol |
65,664 | |
| Filed 2024-03-27 07:03 Tx date 2024-03-24 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$19,278
+2,268 vol $8.50 each |
61,590 | |
| Filed 2024-03-27 07:01 Tx date 2024-03-20 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
-4,537 vol |
59,322 | |
| Filed 2024-03-27 06:57 Tx date 2023-12-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$2,166
+281 vol $7.71 each |
63,859 | |
| Filed 2024-03-27 06:55 Tx date 2023-12-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$9,772
+1,261 vol $7.75 each |
63,578 | |
| Filed 2024-01-26 12:28 Tx date 2024-01-22 |
$LEEF
Leef Brands Inc. |
Wilson, Kevin John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,272
+119,585 vol $0.019 each |
289,822 | |
| Filed 2024-01-26 12:27 Tx date 2024-01-24 |
$LEEF
Leef Brands Inc. |
Wilson, Kevin John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,187
+125,000 vol $0.0175 each |
414,822 | |
| Filed 2024-01-26 12:27 Tx date 2024-01-22 |
$LEEF
Leef Brands Inc. |
Wilson, Kevin John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,277
+119,858 vol $0.019 each |
||
| Filed 2024-01-26 12:26 Tx date 2024-01-19 |
$LEEF
Leef Brands Inc. |
Wilson, Kevin John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,757
+145,142 vol $0.019 each |
170,237 | |
| Filed 2024-01-26 12:24 Tx date 2022-12-01 |
$LEEF
Leef Brands Inc. |
Wilson, Kevin John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
25,095 | ||
| Filed 2023-08-22 19:16 Tx date 2023-08-21 |
$SLMN
Solis Minerals Ltd. |
wilson, kevin
4 - Director of Issuer
Direct Ownership
|
Rights Performance Rights
56 - Grant of rights
|
+600,000 vol |
600,000 | |
| Filed 2023-08-22 19:11 Tx date 2023-08-21 |
$SLMN
Solis Minerals Ltd. |
wilson, kevin
4 - Director of Issuer
Direct Ownership
|
Rights Performance Rights
16 - Acquisition or disposition under a prospectus exemption
|
+600,000 vol |
||
| Filed 2023-08-22 18:22 Tx date 2023-08-21 |
$SLMN
Solis Minerals Ltd. |
wilson, kevin
4 - Director of Issuer
Direct Ownership
|
Rights Performance Rights
16 - Acquisition or disposition under a prospectus exemption
|
+600,000 vol |
600,000 | |
| Filed 2023-08-22 18:22 Tx date 2023-08-21 |
$SLMN
Solis Minerals Ltd. |
wilson, kevin
4 - Director of Issuer
Direct Ownership
|
Rights Performance Rights
16 - Acquisition or disposition under a prospectus exemption
|
+600,000 vol |
||
| Filed 2023-08-22 18:20 Tx date 2021-08-24 |
$SLMN
Solis Minerals Ltd. |
wilson, kevin
4 - Director of Issuer
Direct Ownership
|
Rights Performance Rights
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-08-22 18:19 Tx date 2023-08-21 |
$SLMN
Solis Minerals Ltd. |
wilson, kevin
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$60,000
+109,091 vol $0.55 each |
109,091 | |
| Filed 2023-08-22 18:18 Tx date 2021-08-24 |
$SLMN
Solis Minerals Ltd. |
wilson, kevin
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-06-12 09:25 Tx date 2023-06-02 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-7,996.80
-1,088 vol $7.35 each |
62,317 | |
| Filed 2023-04-01 08:40 Tx date 2023-03-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$29,040
+3,872 vol $7.50 each |
63,405 | |
| Filed 2023-04-01 08:37 Tx date 2023-03-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
-7,744 vol |
59,533 | |
| Filed 2023-03-15 11:33 Tx date 2022-12-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$627.45
+89 vol $7.05 each |
67,277 | |
| Filed 2023-03-15 11:32 Tx date 2022-12-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$8,063
+998 vol $8.08 each |
67,188 | |
| Filed 2022-09-13 18:28 Tx date 2022-08-11 |
$VERS
Verses Technologies Inc. |
Wilson, Kevin Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
10 - Acquisition or disposition in the public market
|
+15,000 vol |
15,000 | |
| Filed 2022-09-13 18:28 Tx date 2021-09-27 |
$VERS
Verses Technologies Inc. |
Wilson, Kevin Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-08-12 10:17 Tx date 2022-08-11 |
$VERS
Verses Technologies Inc. |
Wilson, Kevin Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
10 - Acquisition or disposition in the public market
|
+15,000 vol |
||
| Filed 2022-08-12 10:17 Tx date 2022-08-11 |
$VERS
Verses Technologies Inc. |
Wilson, Kevin Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
10 - Acquisition or disposition in the public market
|
+15,000 vol |
15,000 | |
| Filed 2022-08-12 10:17 Tx date 2021-09-27 |
$VERS
Verses Technologies Inc. |
Wilson, Kevin Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-08-12 10:16 Tx date 2022-08-11 |
$VERS
Verses Technologies Inc. |
Wilson, Kevin Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Subordinate Voting Shares
10 - Acquisition or disposition in the public market
|
$30,000
+30,000 vol $1.00 each |
32,300 | |
| Filed 2022-06-30 10:59 Tx date 2022-06-28 |
$VERS
Verses Technologies Inc. |
Wilson, Kevin Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Subordinate Voting Shares
10 - Acquisition or disposition in the public market
|
$951.28
+2,300 vol $0.4136 each |
2,300 | |
| Filed 2022-06-30 10:58 Tx date 2021-09-27 |
$VERS
Verses Technologies Inc. |
Wilson, Kevin Douglas
5 - Senior Officer of Issuer
Direct Ownership
|
Subordinate Voting Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-04-10 11:12 Tx date 2022-03-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
56 - Grant of rights
|
$33,096
+3,641 vol $9.09 each |
66,190 | |
| Filed 2022-03-29 17:30 Tx date 2022-03-24 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-19,910
-2,200 vol $9.05 each |
62,549 | |
| Filed 2022-03-21 17:35 Tx date 2021-12-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$5,682
+737 vol $7.71 each |
64,749 | |
| Filed 2021-03-22 10:19 Tx date 2021-03-19 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
56 - Grant of rights
|
$32,083
+4,395 vol $7.30 each |
64,012 | |
| Filed 2021-03-12 06:46 Tx date 2020-12-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$2,615
+519 vol $5.04 each |
59,617 | |
| Filed 2020-04-03 08:34 Tx date 2020-03-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
56 - Grant of rights
|
$27,648
+7,659 vol $3.61 each |
59,098 | |
| Filed 2020-03-31 11:43 Tx date 2020-03-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$7,696
+1,050 vol $7.33 each |
51,439 | |
| Filed 2019-03-24 Tx date 2019-03-19 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
50 - Grant of options
|
$25,186
+3,064 vol $8.22 each |
19,951 | |
| Filed 2019-03-06 Tx date 2019-03-05 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$7,500
+787 vol $9.53 each |
50,389 | |
| Filed 2018-10-04 Tx date 2018-09-27 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$-9,705.60
-1,011 vol $9.60 each |
||
| Filed 2018-10-04 Tx date 2018-09-27 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
51 - Exercise of options
|
$6,901
+1,551 vol $4.45 each |
16,887 | |
| Filed 2018-10-04 Tx date 2018-09-27 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,705.60
-1,011 vol $9.60 each |
49,602 | |
| Filed 2018-10-04 Tx date 2018-10-01 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$-9,705.60
-1,011 vol $9.60 each |
||
| Filed 2018-10-02 Tx date 2018-10-01 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$-9,705.60
-1,011 vol $9.60 each |
49,602 | |
| Filed 2018-03-27 Tx date 2017-12-31 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$7,096
+792 vol $8.96 each |
50,613 | |
| Filed 2018-01-09 Tx date 2018-01-09 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
50 - Grant of options
|
$23,366
+2,434 vol $9.60 each |
15,336 | |
| Filed 2017-12-18 Tx date 2017-12-15 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$-14,076.70
-1,474 vol $9.55 each |
49,821 | |
| Filed 2017-07-05 Tx date 2017-07-04 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$70,996
+8,871 vol $8.00 each |
51,295 | |
| Filed 2017-04-04 Tx date 2016-12-12 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-790.00
-100 vol $7.90 each |
0 | |
| Filed 2017-04-04 Tx date 2014-08-28 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-93,000
-10,000 vol $9.30 each |
0 | |
| Filed 2017-04-04 Tx date 2014-06-16 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-37,500
-5,000 vol $7.50 each |
10,000 | |
| Filed 2017-04-04 Tx date 2014-06-12 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-80,500
-10,000 vol $8.05 each |
15,000 | |
| Filed 2017-04-04 Tx date 2014-06-13 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
50 - Grant of options
|
+882 vol |
81,533 | |
| Filed 2017-04-03 Tx date 2016-09-29 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
59 - Exercise for cash
|
$-83,853
-9,900 vol $8.47 each |
||
| Filed 2017-04-03 Tx date 2016-09-29 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-83,853
-9,900 vol $8.47 each |
25,100 | |
| Filed 2017-04-03 Tx date 2016-09-29 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
59 - Exercise for cash
|
$83,853
+9,900 vol $8.47 each |
||
| Filed 2017-04-03 Tx date 2016-09-29 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
59 - Exercise for cash
|
$83,853
+9,900 vol $8.47 each |
||
| Filed 2017-04-03 Tx date 2016-09-29 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
59 - Exercise for cash
|
$-83,853
-9,900 vol $8.47 each |
||
| Filed 2017-03-30 Tx date 2016-09-12 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
51 - Exercise of options
|
$-83,000
-10,000 vol $8.30 each |
74,071 | |
| Filed 2017-03-30 Tx date 2016-09-12 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
51 - Exercise of options
|
$83,000
+10,000 vol $8.30 each |
||
| Filed 2017-03-30 Tx date 2017-03-23 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
50 - Grant of options
|
$468,650
+65,000 vol $7.21 each |
||
| Filed 2017-03-30 Tx date 2017-03-23 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
50 - Grant of options
|
$468,650
+65,000 vol $7.21 each |
||
| Filed 2017-03-30 Tx date 2017-03-23 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-162,772.96
-22,576 vol $7.21 each |
87,324 | |
| Filed 2017-03-30 Tx date 2017-03-23 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$162,772
+22,576 vol $7.21 each |
||
| Filed 2017-03-30 Tx date 2017-03-15 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
50 - Grant of options
|
$21,675
+2,949 vol $7.35 each |
77,020 | |
| Filed 2017-03-30 Tx date 2017-03-23 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
51 - Exercise of options
|
$-468,650
-65,000 vol $7.21 each |
12,020 | |
| Filed 2017-03-30 Tx date 2017-03-15 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
50 - Grant of options
|
$21,675
+2,949 vol $7.35 each |
||
| Filed 2017-03-27 Tx date 2017-03-23 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
50 - Grant of options
|
$468,650
+65,000 vol $7.21 each |
197,476 | |
| Filed 2017-03-24 Tx date 2017-03-23 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$468,650
+65,000 vol $7.21 each |
109,900 | |
| Filed 2017-03-24 Tx date 2017-03-23 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$162,772
+22,576 vol $7.21 each |
132,476 | |
| Filed 2017-03-16 Tx date 2017-03-15 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
50 - Grant of options
|
$21,675
+2,949 vol $7.35 each |
97,020 | |
| Filed 2016-10-05 Tx date 2016-09-29 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
59 - Exercise for cash
|
$83,853
+9,900 vol $8.47 each |
44,900 | |
| Filed 2016-09-19 Tx date 2016-09-12 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$5,699
+10,000 vol $0.57 each |
35,000 | |
| Filed 2016-09-13 Tx date 2016-09-12 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
51 - Exercise of options
|
$83,000
+10,000 vol $8.30 each |
94,071 | |
| Filed 2016-02-18 Tx date 2016-02-12 |
$RX
BioSyent Inc. |
Wilson, Kevin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares - Options
50 - Grant of options
|
$13,658
+2,203 vol $6.20 each |
84,071 |